CID HoldCo Announces Acquisition of Envoy Technologies for $65M

What Happened
CID HoldCo, Inc. (DAIC) announced on September 25, 2026 that it entered into a Securities Purchase Agreement to acquire 100% of Envoy Technologies, Inc. from BladeRanger Ltd. (TASE: BLRN). At Closing (targeted for October 6, 2026), CID will issue an aggregate 10,833,333 shares valued at $65.0 million based on a $6.00 reference price: 233,543 shares of Common Stock to BladeRanger (≈9.99% of shares outstanding immediately prior to Closing) and newly authorized Series C Convertible Preferred stock (8,433,123 shares to BladeRanger and 2,166,667 shares to the holder of a $12.5M Envoy convertible note, subject to that holder joining the agreement). The Series C Preferred is non‑voting (except for protective provisions), convertible one‑for‑one into Common Stock, and subject to a 19.99% ownership blocker until stockholder approval is obtained.

Key Details

• Consideration and structure: 10,833,333 total shares issued; $65,000,000 implied value (Reference Price $6.00/share).
• Closing & approvals: Closing targeted by October 6, 2026; stockholder approval required under Nasdaq Rules (5635) but is not a condition to Closing—parties will use best efforts to obtain approval by Jan 31, 2027.
• Governance & restrictions: BladeRanger may designate one director (board will remain seven members with four independent) and one executive manager while it and affiliates hold ≥10% on an as‑converted basis. BladeRanger’s converted Common shares will be locked up until April 1, 2027 (or six months after conversion) with post‑lockup leak‑out limits.
• Protections & caps: Interim anti‑dilution restrictions until Series C is fully convertible; indemnity reps survive 18 months (fundamental reps 6 years); general indemnity cap equals 25% of the Envoy‑Side Shares’ value at $6.00/share; BladeRanger’s post‑closing indemnity generally satisfied in stock (no cash) except for fraud.

Why It Matters
This transaction will increase CID HoldCo’s outstanding equity and potentially change ownership and board composition (BladeRanger board/designation rights and a sizeable preferred stake convertible into common). The deal creates short‑term limits on CID’s ability to issue dilutive securities and includes post‑closing funding and operational commitments for Envoy (e.g., the Company must contribute certain excess proceeds to Envoy until stockholder approval). Investors should note the need for Nasdaq shareholder approvals (timing risk), the lock‑ups/leak‑out that affect potential share selling, and indemnity/consent mechanics that could affect future cash and equity outcomes.